BTK and B-cell chronic lymphocytic leukemia: Due to its apparent association with the median survival of CLL patients, IGHv is now being used to assist clinicians with treatment decisions and to identify individuals who may benefit from modern therapies, such as ibrutinib, a BTK inhibitor [100].